A new comprehensive review has concluded that medical cannabis is unlikely to provide significant benefits for individuals suffering from mental health conditions, specifically depression and anxiety disorders. This conclusion emerges from a systematic evaluation of data from 54 international clinical studies involving 2,477 patients, with findings published in 'The Lancet Psychiatry'. The research highlights that while medical cannabis is increasingly prescribed for various health issues, its effectiveness in managing psychological disorders needs further scrutiny.

The study conducted by researchers from the University of Sydney examined existing evidence over a broad range of clinical trials spanning from 1980 to 2025. Among the psychological conditions assessed, including post-traumatic stress disorder (PTSD), the researchers found no demonstrable therapeutic benefit of medical cannabis. This calls into question the rising trend of prescribing cannabis and raises concerns about its actual efficacy in treating mental health issues.

While the study outlines key drawbacks, it is essential to recognize that variations in individual responses to medical cannabis do exist, indicating that some patients may experience benefits outside the generalized findings. However, the overall message urges caution in the widespread acceptance of medical cannabis for mental health treatment, emphasizing the need for targeted and rigorous research to understand its true impact on psychological wellbeing and to ensure that patients receive safe and effective care.